Contact

All Stories

  1. Transcriptomic Approach in Understanding Fabry Nephropathy: A Review of the Literature and Proof-of-Concept

    Article • Genes, May 2025, MDPI AG

    Dr Bojan Vujkovac

  2. Telomere Length, Oxidative Stress, and Kidney Damage Biomarkers in Fabry Nephropathy

    Article • Cells, February 2025, MDPI AG

    Dr Bojan Vujkovac

  3. Dynamics of Leukocyte Telomere Length in Patients with Fabry Disease

    Article • Biomedicines, August 2024, MDPI AG

    Dr Bojan Vujkovac

  4. Urinary-derived extracellular vesicles reveal a distinct microRNA signature associated with the development and progression of Fabry nephropathy

    Article • Frontiers in Medicine, March 2023, Frontiers

    Dr Bojan Vujkovac

  5. An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease

    Article • Molecular Genetics and Metabolism, September 2022, Elsevier

    Dr Bojan Vujkovac

  6. Renoprotective Effect of Agalsidase Alfa: A Long-Term Follow-Up of Patients with Fabry Disease

    Article • Journal of Clinical Medicine, August 2022, MDPI AG

    Dr Bojan Vujkovac

  7. Podocyturia in Fabry disease: a 10-year follow-up

    Article • Clinical Kidney Journal, September 2021, Oxford University Press (OUP)

    Dr Bojan Vujkovac

  8. Urinary Extracellular Vesicles and Their miRNA Cargo in Patients with Fabry Nephropathy

    Article • Genes, July 2021, MDPI AG

    Dr Bojan Vujkovac

  9. Characteristics of Vascular Phenotype in Fabry Patients

    Article • Angiology, December 2020, SAGE Publications

    Dr Bojan Vujkovac

  10. Early indicators of disease progression in Fabry disease that may indicate the need for disease-specific treatment initiation: findings from the opinion-based PREDICT-FD modified Delphi consensus initiative

    Article • BMJ Open, October 2020, BMJ

    Dr Bojan Vujkovac

  11. Biomarkers of Fabry Nephropathy: Review and Future Perspective

    Article • Genes, September 2020, MDPI AG

    Dr Bojan Vujkovac

  12. Cardiomyopathy and kidney function in agalsidase beta‐treated female Fabry patients: a pre‐treatment vs. post‐treatment analysis

    Article • ESC Heart Failure, February 2020, Wiley

    Dr Bojan Vujkovac

  13. Switching from agalsidase alfa to pegunigalsidase alfa for treating Fabry disease: One year of treatment data from BRIDGE, a phase III open label study

    Article • Molecular Genetics and Metabolism, February 2020, Elsevier

    Dr Bojan Vujkovac

  14. Aging in Fabry Disease: Role of Telomere Length, Telomerase Activity, and Kidney Disease

    Article • September 2019, Karger Publishers

    Dr Bojan Vujkovac

  15. Analysis of the baseline characteristics of Fabry disease patients screened for the pegunigalsidase alfa phase III BALANCE study

    Article • Molecular Genetics and Metabolism, February 2019, Elsevier

    Dr Bojan Vujkovac

  16. Pegunigalsidase alfa for the treatment of Fabry disease: Preliminary results from a phase III open label, switch over study from agalsidase alfa

    Article • Molecular Genetics and Metabolism, February 2019, Elsevier

    Dr Bojan Vujkovac

  17. Renal and cardiac outcomes in female patients with Fabry disease treated with agalsidase beta: A Fabry registry analysis of pre- versus post-treatment comparison

    Article • Molecular Genetics and Metabolism, February 2019, Elsevier

    Dr Bojan Vujkovac

  18. Fabry disease: diagnostic methods in nephrology practice

    Article • Clinical Nephrology, July 2017, Dustri-Verlgag Dr. Karl Feistle

    Dr Bojan Vujkovac

  19. Paricalcitol as an Antiproteinuric Agent Can Result in the Deterioration of Renal and Heart Function in a Patient with Fabry Disease

    Article • American Journal of Case Reports, June 2017, International Scientific Literature

    Dr Bojan Vujkovac

  20. Renal Replacement Therapy in Slovenia: Excerpts From 2013 Data

    Article • Therapeutic Apheresis and Dialysis, June 2016, Wiley

    Dr Bojan Vujkovac

  21. Anti-proteinuric therapy and Fabry nephropathy; factors associated with preserved kidney function during agalsidase-beta therapy

    Article • Molecular Genetics and Metabolism, February 2016, Elsevier

    Dr Bojan Vujkovac

  22. Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy

    Article • Journal of Medical Genetics, October 2015, BMJ

    Dr Bojan Vujkovac, Christie Thomas

  23. Recommendation for initiation and cessation of enzyme replacement therapy

    Article • Drug Design Development and Therapy, July 2015, Dove Medical Press

    Mr Myrl D. Holida, Dr Reena Sharma, Professor JACEK MUSIAL, Dr Bojan Vujkovac

  24. Exocrine pancreatic insufficiency is not a cause of abdominal complaints in patients with Fabry disease

    Article • Wiener klinische Wochenschrift, April 2015, Springer Science + Business Media

    Dr Bojan Vujkovac

  25. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document

    Article • Orphanet Journal of Rare Diseases, March 2015, Springer Science + Business Media

    Dr Bojan Vujkovac

  26. Exocrine pancreatic insufficiency is not a cause of abdominal complaints in patients with fabry disease

    Article • Pancreatology, June 2014, Elsevier

    Dr Bojan Vujkovac

  27. Renal Replacement Therapy in Slovenia: Excerpts From 2011 Data

    Article • Therapeutic Apheresis and Dialysis, August 2013, Wiley

    Dr Bojan Vujkovac

  28. Recommendations on Reintroduction of Agalsidase Beta for Patients with Fabry Disease in Europe, Following a Period of Shortage

    Article • JIMD Reports, January 2012, Springer Science + Business Media

    Professor Ulla Feldt-Rasmussen, Professor franco cecchi, Dr Bojan Vujkovac

  29. Could Iron Deficiency Also Affect Platelet-Related Hemostasis Impairment in Hemodialysis Patients?: Reply

    Article • Therapeutic Apheresis and Dialysis, August 2011, Wiley

    Dr Bojan Vujkovac

  30. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation

    Article • Nephrology Dialysis Transplantation, July 2011, Oxford University Press (OUP)

    Dr Bojan Vujkovac

  31. Urinary Total Globotriaosylceramide and Isoforms to Identify Women With Fabry Disease: A Diagnostic Test Study

    Article • American Journal of Kidney Diseases, May 2011, Elsevier

    Dr Bojan Vujkovac

  32. Prognostic Indicators of Renal Disease Progression in Adults with Fabry Disease: Natural History Data from the Fabry Registry

    Article • Clinical Journal of the American Society of Nephrology, September 2010, American Society of Nephrology

    prof alberto ortiz , Dr Bojan Vujkovac

  33. Association Between Platelet-Related Hemostasis Impairment and Functional Iron Deficiency in Hemodialysis Patients

    Article • Therapeutic Apheresis and Dialysis, August 2010, Wiley

    Dr Bojan Vujkovac

  34. 143. End stage renal disease in patients with Fabry disease: Natural history data from the Fabry registry

    Article • Molecular Genetics and Metabolism, February 2010, Elsevier

    Dr Bojan Vujkovac

  35. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry

    Article • Nephrology Dialysis Transplantation, October 2009, Oxford University Press (OUP)

    prof alberto ortiz , Dr Bojan Vujkovac

  36. Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN)

    Article • Nephrology Dialysis Transplantation, October 2009, Oxford University Press (OUP)

    Dr Bojan Vujkovac

  37. A successful treatment of life-threatening bleeding from polycystic kidneys with antifibrinolytic agent tranexamic acid

    Article • Blood Coagulation & Fibrinolysis, October 2006, Wolters Kluwer Health

    Dr Bojan Vujkovac

  38. Epoetin Responsiveness in Peritoneal Dialysis Patients: A Multi-center Slovenian Study

    Article • Therapeutic Apheresis and Dialysis, June 2005, Wiley

    Dr Bojan Vujkovac

  39. The effect of long term, low-dose tranexamic acid treatment on platelet dysfunction and haemoglobin levels in haemodialysis patients

    Article • Thrombosis and Haemostasis, January 2005, Thieme Publishing Group

    Dr Bojan Vujkovac

  40. The study of anaemia-related haemostasis impairment in haemodialysis patients by in vitro closure time test

    Article • Thrombosis and Haemostasis, January 2005, Thieme Publishing Group

    Dr Bojan Vujkovac

  41. Remarkable variability in renal disease in a large Slovenian family with Fabry disease

    Article • European Journal of Human Genetics, May 2004, Springer Science + Business Media

    Dr Bojan Vujkovac

  42. Severe Diabetic Ketoacidosis Associated With Acute Myocardial Necrosis

    Article • Diabetes Care, October 2003, American Diabetes Association

    Dr Bojan Vujkovac

  43. Tranexamic acid is beneficial as adjunctive therapy in treating major upper gastrointestinal bleeding in dialysis patients

    Article • Nephrology Dialysis Transplantation, July 2003, Oxford University Press (OUP)

    Dr Bojan Vujkovac

  44. Treatment of subdural and intracerebral haematomas in a haemodialysis patient with tranexamic acid

    Article • Nephrology Dialysis Transplantation, January 2000, Oxford University Press (OUP)

    Dr Bojan Vujkovac

  45. Successful treatment of bleeding from colonic angiodysplasias with tranexamic acid in a hemodialysis patient

    Article • American Journal of Kidney Diseases, March 1998, Elsevier

    Dr Bojan Vujkovac